-
1.
公开(公告)号:US20190030187A1
公开(公告)日:2019-01-31
申请号:US15758312
申请日:2016-09-07
申请人: Sirnaomics, Inc.
发明人: Patrick Y. Lu , Vera Simonenko , Yibin Cai , John Xu , David Evans
IPC分类号: A61K48/00 , A61P31/14 , A61K47/54 , A61K47/28 , C12N15/113
摘要: The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoV) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.
-
公开(公告)号:US12006500B2
公开(公告)日:2024-06-11
申请号:US17157920
申请日:2021-01-25
申请人: Sirnaomics, Inc.
发明人: Danny Tang , Xueping Chen , Patrick Y. Lu , Vera Simonenko , David Evans , John Xu , Deling Wang , Alan Lu
IPC分类号: C12N15/113 , A61K9/51 , A61K31/713 , A61K47/28 , A61K47/69 , A61P31/14
CPC分类号: C12N15/113 , A61K9/513 , A61K31/713 , A61K47/28 , A61K47/6931 , A61P31/14
摘要: Compositions and methods for development of potent siRNA therapeutics for prevention and treatment of Corona Virus (2019-nCoV; COVID-19) infections are provided. The compositions include a pharmaceutical composition comprising siRNA cocktails that target critical viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Administration methods for prevention and treatment are provided, including airway instillation, subcutaneous injections and nebulizer aerosolization.
-
公开(公告)号:US11058779B2
公开(公告)日:2021-07-13
申请号:US15758312
申请日:2016-09-07
申请人: Sirnaomics, Inc.
发明人: Patrick Y. Lu , Vera Simonenko , Yibin Cai , John Xu , David Evans
IPC分类号: A61K48/00 , C12N15/11 , C07H21/02 , C07H21/04 , A61K9/51 , A61K9/127 , A61K47/54 , A61P31/14 , A61K47/28 , C12N15/113 , C12N15/88 , B82Y5/00
摘要: The present invention relates to compositions and methods for siRNA therapeutics for prevention and treatment of Middle East Respiratory Syndrome Corona Virus (MERS-CoV) infections. The compositions include a pharmaceutical composition comprising siRNA cocktails that target viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers.
-
-